GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (NAS:NBSE) » Definitions » Net Margin %

NeuBase Therapeutics (NeuBase Therapeutics) Net Margin % : 0.00% (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is NeuBase Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. NeuBase Therapeutics's Net Income for the three months ended in Sep. 2023 was $-1.82 Mil. NeuBase Therapeutics's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, NeuBase Therapeutics's net margin for the quarter that ended in Sep. 2023 was 0.00%.

The historical rank and industry rank for NeuBase Therapeutics's Net Margin % or its related term are showing as below:


NBSE's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -148.36
* Ranked among companies with meaningful Net Margin % only.

NeuBase Therapeutics Net Margin % Historical Data

The historical data trend for NeuBase Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Net Margin % Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NeuBase Therapeutics's Net Margin %

For the Biotechnology subindustry, NeuBase Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuBase Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuBase Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where NeuBase Therapeutics's Net Margin % falls into.



NeuBase Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

NeuBase Therapeutics's Net Margin for the fiscal year that ended in Sep. 2021 is calculated as

Net Margin=Net Income (A: Sep. 2021 )/Revenue (A: Sep. 2021 )
=-25.409/0
= %

NeuBase Therapeutics's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin=Net Income (Q: Sep. 2023 )/Revenue (Q: Sep. 2023 )
=-1.821/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeuBase Therapeutics  (NAS:NBSE) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


NeuBase Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of NeuBase Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuBase Therapeutics (NeuBase Therapeutics) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.
Executives
Symetryx Corp 10 percent owner 2828 BATHURST ST #400, TORONTO A6 M6B3A7
Aleta Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
Barry Shiff 10 percent owner 461 LYTTON BLVD., TORONTO A6 M5N 1S5
William Roland Mann officer: COO 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Todd P. Branning officer: Chief Financial Officer C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Sandra Rojas-caro officer: Chief Medical Officer C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746
Kianoush Motesharei officer: See Remarks 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Gerald J Mcdougall director 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219
Curt Bradshaw officer: Chief Scientific Officer 177 E COLORADO BLVD, STE 700, PASADENA CA 91105
Gines Diego Miralles director 2235 VIA FRESCA, LA JOLLA CA 92037
Franklyn G Prendergast director
Dietrich A Stephan director, 10 percent owner, officer: President and CEO 213 SMITHFIELD ST, PITTSBURGH PA 15222
Lipizzaner Llc 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801